Combining stereotactic body radiation therapy with immunotherapy: current data and future directions

doi:10.21037/tlcr.2018.08.16

Review

. 2019 Feb;8(1):107-115.

doi: 10.21037/tlcr.2018.08.16.

Combining stereotactic body radiation therapy with immunotherapy: current data and future directions

Alexander J Lin¹, Michael Roach¹, Jeffrey Bradley¹, Clifford Robinson¹

Affiliations

PMID: 30788240
PMCID: PMC6351396
DOI: 10.21037/tlcr.2018.08.16

Review

Combining stereotactic body radiation therapy with immunotherapy: current data and future directions

Alexander J Lin et al. Transl Lung Cancer Res. 2019 Feb.

. 2019 Feb;8(1):107-115.

doi: 10.21037/tlcr.2018.08.16.

Authors

Alexander J Lin¹, Michael Roach¹, Jeffrey Bradley¹, Clifford Robinson¹

Affiliation

¹ Department of Radiation Oncology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.

PMID: 30788240
PMCID: PMC6351396
DOI: 10.21037/tlcr.2018.08.16

Abstract

Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect. This review summarizes the current data in the fast-changing field of immuno-radiation therapy, highlighting updates from recent clinical trials.

Keywords: Stereotactic body radiation therapy (SBRT); checkpoint inhibitor; immunotherapy; lung cancer; stereotactic ablative radiotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Cited by

A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
Duda D, Gkika E, Firat E, Adebahr S, Graf E, Eichhorst A, Radicioni G, Lo S, Spohn S, Nestle U, Nicolay N, Niedermann G, Grosu AL. Duda D, et al. Res Sq [Preprint]. 2023 Nov 14:rs.3.rs-3547043. doi: 10.21203/rs.3.rs-3547043/v1. Res Sq. 2023. PMID: 38014120 Free PMC article. Preprint.
Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer.
Hannon G, Lesch ML, Gerber SA. Hannon G, et al. Int J Mol Sci. 2023 Apr 16;24(8):7359. doi: 10.3390/ijms24087359. Int J Mol Sci. 2023. PMID: 37108522 Free PMC article. Review.
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.
Gkika E, Firat E, Adebahr S, Graf E, Popp I, Radicioni G, Lo SS, Nestle U, Nicolay NH, Niedermann G, Duda DG, Grosu AL. Gkika E, et al. NPJ Precis Oncol. 2023 Mar 2;7(1):24. doi: 10.1038/s41698-023-00358-z. NPJ Precis Oncol. 2023. PMID: 36864234 Free PMC article.
The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study.
Seyedin SN, Bassalow R, Mawlawi OR, Turner LM, Patel RR, Mazin SR, Oderinde OM, Voronenko Y, Wages CA, Olcott PD, Chang JY, Balter PA, Welsh JW. Seyedin SN, et al. Front Oncol. 2022 Oct 14;12:921473. doi: 10.3389/fonc.2022.921473. eCollection 2022. Front Oncol. 2022. PMID: 36313653 Free PMC article.
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.
van der Woude LL, Gorris MAJ, Wortel IMN, Creemers JHA, Verrijp K, Monkhorst K, Grünberg K, van den Heuvel MM, Textor J, Figdor CG, Piet B, Theelen WSME, de Vries IJM. van der Woude LL, et al. J Immunother Cancer. 2022 Oct;10(10):e005248. doi: 10.1136/jitc-2022-005248. J Immunother Cancer. 2022. PMID: 36252995 Free PMC article.

See all "Cited by" articles

References

1. Caillet V, Booth JT, Keall P. IGRT and motion management during lung SBRT delivery. Phys Med 2017;44:113-22. 10.1016/j.ejmp.2017.06.006 - DOI - PubMed
1. Chua KLM, Sin I, Fong KW, et al. Stereotactic body radiotherapy for early stage lung cancer—historical developments and future strategies. Chin Clin Oncol 2017;6:S20. 10.21037/cco.2017.08.02 - DOI - PubMed
1. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35. 10.6004/jnccn.2017.0050 - DOI - PubMed
1. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6. 10.1001/jama.2010.261 - DOI - PMC - PubMed
1. Timmerman RD, Hu C, Michalski J, et al. Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol 2014;90:S30 10.1016/j.ijrobp.2014.05.135 - DOI

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect

[1] Caillet V, Booth JT, Keall P. IGRT and motion management during lung SBRT delivery. Phys Med 2017;44:113-22. 10.1016/j.ejmp.2017.06.006 - DOI - PubMed

[2] Caillet V, Booth JT, Keall P. IGRT and motion management during lung SBRT delivery. Phys Med 2017;44:113-22. 10.1016/j.ejmp.2017.06.006 - DOI - PubMed

[3] Chua KLM, Sin I, Fong KW, et al. Stereotactic body radiotherapy for early stage lung cancer—historical developments and future strategies. Chin Clin Oncol 2017;6:S20. 10.21037/cco.2017.08.02 - DOI - PubMed

[4] Chua KLM, Sin I, Fong KW, et al. Stereotactic body radiotherapy for early stage lung cancer—historical developments and future strategies. Chin Clin Oncol 2017;6:S20. 10.21037/cco.2017.08.02 - DOI - PubMed

[5] Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35. 10.6004/jnccn.2017.0050 - DOI - PubMed

[6] Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35. 10.6004/jnccn.2017.0050 - DOI - PubMed

[7] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6. 10.1001/jama.2010.261 - DOI - PMC - PubMed

[8] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6. 10.1001/jama.2010.261 - DOI - PMC - PubMed

[9] Timmerman RD, Hu C, Michalski J, et al. Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol 2014;90:S30 10.1016/j.ijrobp.2014.05.135 - DOI

[10] Timmerman RD, Hu C, Michalski J, et al. Long-term Results of RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Medically Inoperable Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol 2014;90:S30 10.1016/j.ijrobp.2014.05.135 - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Combining stereotactic body radiation therapy with immunotherapy: current data and future directions

Affiliation

Combining stereotactic body radiation therapy with immunotherapy: current data and future directions

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources